Trial Outcomes & Findings for Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients (NCT NCT05502081)

NCT ID: NCT05502081

Last Updated: 2023-07-25

Results Overview

Dead or alive

• Recruitment status: COMPLETED
• Study phase: PHASE4
• Target enrollment: 265 participants
• Primary outcome timeframe: 28 days
• Results posted on: 2023-07-25

Participant Flow

from 1/11/2021 to 29/5/2022 at isolation hospital, Mansoura university

assignment is applied after admission of participants

Participant milestones

Measure	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies	Remdesivir Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug
Overall Study STARTED	53	106	106
Overall Study COMPLETED	53	106	106
Overall Study NOT COMPLETED	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients

Baseline characteristics by cohort

Measure	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Total n=265 Participants Total of all reporting groups
Age, Continuous	58.34 years STANDARD_DEVIATION 16.096 • n=5 Participants	59.3 years STANDARD_DEVIATION 15.98 • n=7 Participants	65.02 years STANDARD_DEVIATION 14.26 • n=5 Participants	60.88 years STANDARD_DEVIATION 15.44 • n=4 Participants
Sex: Female, Male Female	24 Participants n=5 Participants	42 Participants n=7 Participants	61 Participants n=5 Participants	127 Participants n=4 Participants
Sex: Female, Male Male	29 Participants n=5 Participants	64 Participants n=7 Participants	45 Participants n=5 Participants	138 Participants n=4 Participants
Race/Ethnicity, Customized Middle eastern	53 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	265 Participants n=4 Participants
Number of co-morbidities 0	10 Participants n=5 Participants	32 Participants n=7 Participants	22 Participants n=5 Participants	64 Participants n=4 Participants
Number of co-morbidities 1	16 Participants n=5 Participants	27 Participants n=7 Participants	19 Participants n=5 Participants	62 Participants n=4 Participants
Number of co-morbidities 2	14 Participants n=5 Participants	28 Participants n=7 Participants	33 Participants n=5 Participants	75 Participants n=4 Participants
Number of co-morbidities 3	11 Participants n=5 Participants	16 Participants n=7 Participants	18 Participants n=5 Participants	45 Participants n=4 Participants
Number of co-morbidities 4	2 Participants n=5 Participants	2 Participants n=7 Participants	10 Participants n=5 Participants	14 Participants n=4 Participants
Number of co-morbidities 5	0 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants
Number of co-morbidities 6	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Method of diagnosis symptoms	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Method of diagnosis laboratory and radiology	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Method of diagnosis polymerase chain reaction confirmed	53 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	265 Participants n=4 Participants
Severity of COVID-19 moderate	18 Participants n=5 Participants	20 Participants n=7 Participants	20 Participants n=5 Participants	58 Participants n=4 Participants
Severity of COVID-19 severe	27 Participants n=5 Participants	60 Participants n=7 Participants	53 Participants n=5 Participants	140 Participants n=4 Participants
Severity of COVID-19 critical	8 Participants n=5 Participants	26 Participants n=7 Participants	33 Participants n=5 Participants	67 Participants n=4 Participants
World health organization clinical progression scale 3	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
World health organization clinical progression scale 4	15 Participants n=5 Participants	5 Participants n=7 Participants	10 Participants n=5 Participants	30 Participants n=4 Participants
World health organization clinical progression scale 5	35 Participants n=5 Participants	100 Participants n=7 Participants	96 Participants n=5 Participants	231 Participants n=4 Participants
World health organization clinical progression scale 6	3 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	3 Participants n=4 Participants
Number of symptoms 2	4 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	8 Participants n=4 Participants
Number of symptoms 3	13 Participants n=5 Participants	6 Participants n=7 Participants	4 Participants n=5 Participants	23 Participants n=4 Participants
Number of symptoms 4	32 Participants n=5 Participants	97 Participants n=7 Participants	97 Participants n=5 Participants	226 Participants n=4 Participants
Number of symptoms 5	4 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	8 Participants n=4 Participants
Antibiotics use yes	53 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	265 Participants n=4 Participants
Antibiotics use no	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
macrolide use yes	8 Participants n=5 Participants	8 Participants n=7 Participants	2 Participants n=5 Participants	18 Participants n=4 Participants
macrolide use no	45 Participants n=5 Participants	98 Participants n=7 Participants	104 Participants n=5 Participants	247 Participants n=4 Participants
fluoroquinolone use yes	41 Participants n=5 Participants	92 Participants n=7 Participants	95 Participants n=5 Participants	228 Participants n=4 Participants
fluoroquinolone use no	12 Participants n=5 Participants	14 Participants n=7 Participants	11 Participants n=5 Participants	37 Participants n=4 Participants
cephalosporin use yes	39 Participants n=5 Participants	86 Participants n=7 Participants	83 Participants n=5 Participants	208 Participants n=4 Participants
cephalosporin use no	14 Participants n=5 Participants	20 Participants n=7 Participants	23 Participants n=5 Participants	57 Participants n=4 Participants
carbapenem use yes	10 Participants n=5 Participants	32 Participants n=7 Participants	22 Participants n=5 Participants	64 Participants n=4 Participants
carbapenem use no	43 Participants n=5 Participants	74 Participants n=7 Participants	84 Participants n=5 Participants	201 Participants n=4 Participants
piperacillin use yes	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
piperacillin use no	53 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	265 Participants n=4 Participants
amoxicillin/ clavulanate use yes	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
amoxicillin/ clavulanate use no	53 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	265 Participants n=4 Participants
co-trimoxazole use yes	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
co-trimoxazole use no	53 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	265 Participants n=4 Participants
linezolide use yes	5 Participants n=5 Participants	12 Participants n=7 Participants	4 Participants n=5 Participants	21 Participants n=4 Participants
linezolide use no	48 Participants n=5 Participants	94 Participants n=7 Participants	102 Participants n=5 Participants	244 Participants n=4 Participants
teicoplanin use yes	1 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants
teicoplanin use no	52 Participants n=5 Participants	106 Participants n=7 Participants	104 Participants n=5 Participants	262 Participants n=4 Participants
Anticoagulant use yes	49 Participants n=5 Participants	101 Participants n=7 Participants	96 Participants n=5 Participants	246 Participants n=4 Participants
Anticoagulant use no	4 Participants n=5 Participants	5 Participants n=7 Participants	10 Participants n=5 Participants	19 Participants n=4 Participants
dose of anticoagulant prophylactic	39 Participants n=5 Participants	80 Participants n=7 Participants	81 Participants n=5 Participants	200 Participants n=4 Participants
dose of anticoagulant therapeutic	14 Participants n=5 Participants	26 Participants n=7 Participants	25 Participants n=5 Participants	65 Participants n=4 Participants
Antiplatelet use yes	5 Participants n=5 Participants	6 Participants n=7 Participants	0 Participants n=5 Participants	11 Participants n=4 Participants
Antiplatelet use no	48 Participants n=5 Participants	100 Participants n=7 Participants	106 Participants n=5 Participants	254 Participants n=4 Participants
Steriods use yes	45 Participants n=5 Participants	105 Participants n=7 Participants	98 Participants n=5 Participants	248 Participants n=4 Participants
Steriods use no	8 Participants n=5 Participants	1 Participants n=7 Participants	8 Participants n=5 Participants	17 Participants n=4 Participants
Additive therapy use yes	51 Participants n=5 Participants	106 Participants n=7 Participants	105 Participants n=5 Participants	262 Participants n=4 Participants
Additive therapy use no	2 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants
paracetamol use yes	50 Participants n=5 Participants	105 Participants n=7 Participants	106 Participants n=5 Participants	261 Participants n=4 Participants
paracetamol use no	3 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants
zinc use yes	4 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	5 Participants n=4 Participants
zinc use no	49 Participants n=5 Participants	106 Participants n=7 Participants	105 Participants n=5 Participants	260 Participants n=4 Participants
acetylcysteine use yes	52 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	264 Participants n=4 Participants
acetylcysteine use no	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
lactoferrin use yes	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
lactoferrin use no	52 Participants n=5 Participants	106 Participants n=7 Participants	106 Participants n=5 Participants	264 Participants n=4 Participants
vitamin C use yes	4 Participants n=5 Participants	7 Participants n=7 Participants	1 Participants n=5 Participants	12 Participants n=4 Participants
vitamin C use no	49 Participants n=5 Participants	99 Participants n=7 Participants	105 Participants n=5 Participants	253 Participants n=4 Participants
Oxygen therapy use yes	37 Participants n=5 Participants	99 Participants n=7 Participants	102 Participants n=5 Participants	238 Participants n=4 Participants
Oxygen therapy use no	16 Participants n=5 Participants	7 Participants n=7 Participants	4 Participants n=5 Participants	27 Participants n=4 Participants
Nasal Prongs use yes	18 Participants n=5 Participants	35 Participants n=7 Participants	39 Participants n=5 Participants	92 Participants n=4 Participants
Nasal Prongs use no	35 Participants n=5 Participants	71 Participants n=7 Participants	67 Participants n=5 Participants	173 Participants n=4 Participants
Simple Face Mask use yes	30 Participants n=5 Participants	82 Participants n=7 Participants	87 Participants n=5 Participants	199 Participants n=4 Participants
Simple Face Mask use no	23 Participants n=5 Participants	24 Participants n=7 Participants	19 Participants n=5 Participants	66 Participants n=4 Participants
Mask Reservoir use yes	8 Participants n=5 Participants	33 Participants n=7 Participants	14 Participants n=5 Participants	55 Participants n=4 Participants
Mask Reservoir use no	45 Participants n=5 Participants	73 Participants n=7 Participants	92 Participants n=5 Participants	210 Participants n=4 Participants
High Flow Nasal Cannula use yes	5 Participants n=5 Participants	22 Participants n=7 Participants	18 Participants n=5 Participants	45 Participants n=4 Participants
High Flow Nasal Cannula use no	48 Participants n=5 Participants	84 Participants n=7 Participants	88 Participants n=5 Participants	220 Participants n=4 Participants
Continuous Positive Attenuated Pressure use yes	4 Participants n=5 Participants	39 Participants n=7 Participants	36 Participants n=5 Participants	79 Participants n=4 Participants
Continuous Positive Attenuated Pressure use no	49 Participants n=5 Participants	67 Participants n=7 Participants	70 Participants n=5 Participants	186 Participants n=4 Participants
Invasive Mechanical Ventilation use yes	1 Participants n=5 Participants	29 Participants n=7 Participants	29 Participants n=5 Participants	59 Participants n=4 Participants
Invasive Mechanical Ventilation use no	52 Participants n=5 Participants	77 Participants n=7 Participants	77 Participants n=5 Participants	206 Participants n=4 Participants
Vasopressor use yes	0 Participants n=5 Participants	23 Participants n=7 Participants	18 Participants n=5 Participants	41 Participants n=4 Participants
Vasopressor use no	53 Participants n=5 Participants	83 Participants n=7 Participants	88 Participants n=5 Participants	224 Participants n=4 Participants
Prone Positioning yes	0 Participants n=5 Participants	5 Participants n=7 Participants	9 Participants n=5 Participants	14 Participants n=4 Participants
Prone Positioning no	53 Participants n=5 Participants	101 Participants n=7 Participants	97 Participants n=5 Participants	251 Participants n=4 Participants
Heart rate	82.40 beats/ minute STANDARD_DEVIATION 12.443 • n=5 Participants	85.7 beats/ minute STANDARD_DEVIATION 16.072 • n=7 Participants	87.02 beats/ minute STANDARD_DEVIATION 16.79 • n=5 Participants	85.04 beats/ minute STANDARD_DEVIATION 15.1 • n=4 Participants
Respiratory rate	24.25 breaths/ minute STANDARD_DEVIATION 3.246 • n=5 Participants	25.4 breaths/ minute STANDARD_DEVIATION 5.58 • n=7 Participants	24.72 breaths/ minute STANDARD_DEVIATION 5.012 • n=5 Participants	24.79 breaths/ minute STANDARD_DEVIATION 4.612 • n=4 Participants
Body temperature	36.951 degree Celsius STANDARD_DEVIATION 0.492 • n=5 Participants	36.938 degree Celsius STANDARD_DEVIATION 0.456 • n=7 Participants	36.906 degree Celsius STANDARD_DEVIATION 1.18 • n=5 Participants	36.92 degree Celsius STANDARD_DEVIATION 0.709 • n=4 Participants
O2 saturation on Oxygen therapy	96.26 percentage of O2 saturation STANDARD_DEVIATION 2.391 • n=5 Participants	95.86 percentage of O2 saturation STANDARD_DEVIATION 3.795 • n=7 Participants	96.01 percentage of O2 saturation STANDARD_DEVIATION 3.130 • n=5 Participants	96.04 percentage of O2 saturation STANDARD_DEVIATION 3.105 • n=4 Participants
O2 saturation on Room air	92.36 percentage of O2 saturation STANDARD_DEVIATION 4.816 • n=5 Participants	87.62 percentage of O2 saturation STANDARD_DEVIATION 7.171 • n=7 Participants	88.35 percentage of O2 saturation STANDARD_DEVIATION 7.006 • n=5 Participants	89.44 percentage of O2 saturation STANDARD_DEVIATION 6.33 • n=4 Participants
Aspartate aminotransferase level	45.62 Units/liter STANDARD_DEVIATION 38.619 • n=5 Participants	52.95 Units/liter STANDARD_DEVIATION 35.49 • n=7 Participants	54.52 Units/liter STANDARD_DEVIATION 67.85 • n=5 Participants	51.03 Units/liter STANDARD_DEVIATION 47.319 • n=4 Participants
Alanine aminotransferase level	33.34 Units/liter STANDARD_DEVIATION 27.166 • n=5 Participants	33.27 Units/liter STANDARD_DEVIATION 22.826 • n=7 Participants	42.79 Units/liter STANDARD_DEVIATION 77.37 • n=5 Participants	36.46 Units/liter STANDARD_DEVIATION 42.454 • n=4 Participants
Bilirubin level	0.5472 milligram/deciliter STANDARD_DEVIATION 0.299 • n=5 Participants	0.6228 milligram/deciliter STANDARD_DEVIATION 0.79 • n=7 Participants	0.7327 milligram/deciliter STANDARD_DEVIATION 0.69 • n=5 Participants	0.634 milligram/deciliter STANDARD_DEVIATION 0.593 • n=4 Participants
Albumin level	3.1774 gram/deciliter STANDARD_DEVIATION 0.461 • n=5 Participants	3.1715 gram/deciliter STANDARD_DEVIATION 0.48 • n=7 Participants	3.1021 gram/deciliter STANDARD_DEVIATION 0.512 • n=5 Participants	3.15 gram/deciliter STANDARD_DEVIATION 0.484 • n=4 Participants
Prothrombin Time	14.575 seconds STANDARD_DEVIATION 1.68 • n=5 Participants	15.338 seconds STANDARD_DEVIATION 1.997 • n=7 Participants	15.69 seconds STANDARD_DEVIATION 2.476 • n=5 Participants	15.201 seconds STANDARD_DEVIATION 2.051 • n=4 Participants
International normalized ratio	1.2625 Ratio STANDARD_DEVIATION 0.201 • n=5 Participants	1.3436 Ratio STANDARD_DEVIATION 0.239 • n=7 Participants	1.3868 Ratio STANDARD_DEVIATION 0.296 • n=5 Participants	1.33 Ratio STANDARD_DEVIATION 0.245 • n=4 Participants
Serum creatinine	1.2092 milligram/deciliter STANDARD_DEVIATION 1.355 • n=5 Participants	1.0999 milligram/deciliter STANDARD_DEVIATION 0.924 • n=7 Participants	1.8807 milligram/deciliter STANDARD_DEVIATION 1.912 • n=5 Participants	1.3966 milligram/deciliter STANDARD_DEVIATION 1.397 • n=4 Participants
Total leukocytic count	8.6934 10^3 cells/mm^3 STANDARD_DEVIATION 4.129 • n=5 Participants	8.4562 10^3 cells/mm^3 STANDARD_DEVIATION 5.044 • n=7 Participants	11.0268 10^3 cells/mm^3 STANDARD_DEVIATION 9.4 • n=5 Participants	9.39 10^3 cells/mm^3 STANDARD_DEVIATION 6.191 • n=4 Participants
Lymphocyte count	0.9658 10^9 cells/L STANDARD_DEVIATION 0.521 • n=5 Participants	0.9123 10^9 cells/L STANDARD_DEVIATION 0.429 • n=7 Participants	1.4834 10^9 cells/L STANDARD_DEVIATION 5.62 • n=5 Participants	1.12 10^9 cells/L STANDARD_DEVIATION 2.19 • n=4 Participants
Hemoglobin level	12.59 gram/deciliter STANDARD_DEVIATION 1.58 • n=5 Participants	12.44 gram/deciliter STANDARD_DEVIATION 2.07 • n=7 Participants	11.94 gram/deciliter STANDARD_DEVIATION 2.54 • n=5 Participants	12.32 gram/deciliter STANDARD_DEVIATION 2.063 • n=4 Participants
Hematocrit level	39.317 percentage of total blood volume STANDARD_DEVIATION 6.045 • n=5 Participants	36.975 percentage of total blood volume STANDARD_DEVIATION 5.586 • n=7 Participants	35.259 percentage of total blood volume STANDARD_DEVIATION 8.559 • n=5 Participants	37.18 percentage of total blood volume STANDARD_DEVIATION 6.73 • n=4 Participants
Platelet count	234.913 10^3 cells/uL STANDARD_DEVIATION 91.5 • n=5 Participants	211.613 10^3 cells/uL STANDARD_DEVIATION 92.3 • n=7 Participants	217.591 10^3 cells/uL STANDARD_DEVIATION 122 • n=5 Participants	221.37 10^3 cells/uL STANDARD_DEVIATION 101.93 • n=4 Participants
Lactate dehydrogenase level	413.06 international units per liter STANDARD_DEVIATION 294.7 • n=5 Participants	389.81 international units per liter STANDARD_DEVIATION 222.668 • n=7 Participants	378.5 international units per liter STANDARD_DEVIATION 250.183 • n=5 Participants	393.79 international units per liter STANDARD_DEVIATION 255.85 • n=4 Participants
Creatine kinase level	185.96 Units/liter STANDARD_DEVIATION 207.6 • n=5 Participants	228.07 Units/liter STANDARD_DEVIATION 367.1 • n=7 Participants	232.75 Units/liter STANDARD_DEVIATION 287 • n=5 Participants	215.59 Units/liter STANDARD_DEVIATION 287.23 • n=4 Participants
D-dimer level	0.6189 μg/mL STANDARD_DEVIATION 0.493 • n=5 Participants	0.1433 μg/mL STANDARD_DEVIATION 0.227 • n=7 Participants	0.2915 μg/mL STANDARD_DEVIATION 0.385 • n=5 Participants	0.351 μg/mL STANDARD_DEVIATION 0.368 • n=4 Participants
C-reactive protein level	61.566 milligram/liter STANDARD_DEVIATION 39.71 • n=5 Participants	61.292 milligram/liter STANDARD_DEVIATION 35.3 • n=7 Participants	95.513 milligram/liter STANDARD_DEVIATION 157.8 • n=5 Participants	72.79 milligram/liter STANDARD_DEVIATION 77.60 • n=4 Participants
Ferritin level	442.34 micrograms per liter STANDARD_DEVIATION 190.4 • n=5 Participants	418.06 micrograms per liter STANDARD_DEVIATION 193.8 • n=7 Participants	1158.4 micrograms per liter STANDARD_DEVIATION 6953 • n=5 Participants	672.93 micrograms per liter STANDARD_DEVIATION 2445.73 • n=4 Participants
Sodium level	146.472 millimole/liter STANDARD_DEVIATION 30.7 • n=5 Participants	145.243 millimole/liter STANDARD_DEVIATION 20 • n=7 Participants	144.315 millimole/liter STANDARD_DEVIATION 18.5 • n=5 Participants	145.34 millimole/liter STANDARD_DEVIATION 23.06 • n=4 Participants
Potassium level	3.6228 millimole/liter STANDARD_DEVIATION 0.514 • n=5 Participants	3.47 millimole/liter STANDARD_DEVIATION 0.674 • n=7 Participants	3.79 millimole/liter STANDARD_DEVIATION 0.829 • n=5 Participants	3.627 millimole/liter STANDARD_DEVIATION 0.672 • n=4 Participants
arterial oxygen pressure	36.689 millimeters of mercury STANDARD_DEVIATION 12.59 • n=5 Participants	37.325 millimeters of mercury STANDARD_DEVIATION 14.6 • n=7 Participants	37.603 millimeters of mercury STANDARD_DEVIATION 12.08 • n=5 Participants	37.205 millimeters of mercury STANDARD_DEVIATION 13.09 • n=4 Participants
ratio of arterial Oxygen pressure to fraction inspired of Oxygen	223.5057 Ratio STANDARD_DEVIATION 207 • n=5 Participants	156.7358 Ratio STANDARD_DEVIATION 171 • n=7 Participants	164.142 Ratio STANDARD_DEVIATION 138 • n=5 Participants	181.46 Ratio STANDARD_DEVIATION 516 • n=4 Participants
Glasgow coma score 4	0 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants
Glasgow coma score 6	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
Glasgow coma score 8	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Glasgow coma score 9	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants
Glasgow coma score 10	0 Participants n=5 Participants	2 Participants n=7 Participants	8 Participants n=5 Participants	10 Participants n=4 Participants
Glasgow coma score 13	0 Participants n=5 Participants	0 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants
Glasgow coma score 14	1 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants	12 Participants n=4 Participants
Glasgow coma score 15	52 Participants n=5 Participants	97 Participants n=7 Participants	86 Participants n=5 Participants	235 Participants n=4 Participants
Sequential organ function assessment 0	11 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	14 Participants n=4 Participants
Sequential organ function assessment 1	1 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	6 Participants n=4 Participants
Sequential organ function assessment 2	3 Participants n=5 Participants	9 Participants n=7 Participants	3 Participants n=5 Participants	15 Participants n=4 Participants
Sequential organ function assessment 3	12 Participants n=5 Participants	25 Participants n=7 Participants	17 Participants n=5 Participants	54 Participants n=4 Participants
Sequential organ function assessment 4	17 Participants n=5 Participants	36 Participants n=7 Participants	28 Participants n=5 Participants	81 Participants n=4 Participants
Sequential organ function assessment 5	7 Participants n=5 Participants	18 Participants n=7 Participants	17 Participants n=5 Participants	42 Participants n=4 Participants
Sequential organ function assessment 6	0 Participants n=5 Participants	6 Participants n=7 Participants	13 Participants n=5 Participants	19 Participants n=4 Participants
Sequential organ function assessment 7	2 Participants n=5 Participants	4 Participants n=7 Participants	9 Participants n=5 Participants	15 Participants n=4 Participants
Sequential organ function assessment 8	0 Participants n=5 Participants	3 Participants n=7 Participants	7 Participants n=5 Participants	10 Participants n=4 Participants
Sequential organ function assessment 9	0 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants
Sequential organ function assessment 10	0 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants
Sequential organ function assessment 14	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants

PRIMARY outcome

Timeframe: 28 days

Dead or alive

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
28-days Mortality Rate dead	34 Participants	43 Participants	1 Participants
28-days Mortality Rate alive	72 Participants	63 Participants	52 Participants

PRIMARY outcome

Timeframe: up to 60 days

positive or negative

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit positive	92 Participants	78 Participants	36 Participants
Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit negative	14 Participants	28 Participants	17 Participants

PRIMARY outcome

Timeframe: up to 60 days

yes or no

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Number of Participants With Infusion Related Reactions, Hypersensitivity Reactions and Any Serious Adverse Events yes	0 Participants	0 Participants	0 Participants
Number of Participants With Infusion Related Reactions, Hypersensitivity Reactions and Any Serious Adverse Events no	106 Participants	106 Participants	53 Participants

SECONDARY outcome

Timeframe: up to 60 days

yes or no

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Need for Invasive Mechanical Ventilation yes	22 Participants	22 Participants	1 Participants
Need for Invasive Mechanical Ventilation no	84 Participants	84 Participants	52 Participants

SECONDARY outcome

Timeframe: up to 60 days

in days

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Oxygen Support Duration (Days)	9.2 days Standard Deviation 7.107	7.46 days Standard Deviation 5.077	3.72 days Standard Deviation 3.527

SECONDARY outcome

Timeframe: up to 60 days

in days

WHO disease ordinal progression scale 0= Uninfected Ambulatory mild disease

1. Asymptomatic; viral RNA detected

2. Symptomatic; independent.

3. Symptomatic; assistance needed Hospitalized: moderate disease

4. Hospitalized; no oxygen therapy

5. Hospitalized; oxygen by mask or nasal prongs Hospitalized: sever disease

6. Hospitalized; oxygen by NIV or high flow

7. Intubation and mechanical ventilation, pO2 /FIO2 ≥ 150 or Spo2 /FiO2 ≥200

8. Mechanical ventilation pO2/FiO2 <150 (SpO2 /FiO2 < 200) or vasopressors

9. Mechanical ventilation pO2 / FiO2 < 150 and vasopressors, dialysis or ECMO Dead

10. Dead

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Time to Clinical Improvement (Defined as 2 Points Reduction in the WHO Disease Ordinal Progression Scale or Discharge, Whatever Happens First	8.33 days Standard Deviation 6.38	7.75 days Standard Deviation 4.265	7.4 days Standard Deviation 3.101

SECONDARY outcome

Timeframe: up to 60 days

in days

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Duration of Hospitalization	11.85 days Standard Deviation 6.264	10.59 days Standard Deviation 5.26	8.94 days Standard Deviation 3.165

SECONDARY outcome

Timeframe: Day 3

minimum 0 to maximum 24, higher scores mean worse outcomes Platelets, ×10³/µL

≥150 0 100-149+1 50-99+2 20-49+3 <20+4

Glasgow Coma Scale If on sedatives, estimate assumed GCS off sedatives 15 0 13-14+1 10-12+2 6-9+3 <6+4

Bilirubin, mg/dL (μmol/L) <1.2 (<20) 0 1.2-1.9 (20-32)+1 2.0-5.9 (33-101)+2 6.0-11.9 (102-204)+3 ≥12.0 (>204)+4

Mean arterial pressure OR administration of vasoactive agents required Listed doses are in units of mcg/kg/min No hypotension 0 MAP <70 mmHg+1 DOPamine ≤5 or DOBUTamine (any dose)+2 DOPamine >5, EPINEPHrine ≤0.1, or norEPINEPHrine ≤0.1+3 DOPamine >15, EPINEPHrine >0.1, or norEPINEPHrine >0.1+4

Creatinine, mg/dL (μmol/L) (or urine output) <1.2 (<110) 0 1.2-1.9 (110-170)+1 2.0-3.4 (171-299)+2 3.5-4.9 (300-440) or UOP <500 mL/day+3

≥5.0 (>440) or UOP <200 mL/day+4

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Sequential Organ Function Assessment (SOFA) Score on Day 3 0	1 Participants	1 Participants	12 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 1	8 Participants	6 Participants	3 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 2	12 Participants	8 Participants	12 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 3	24 Participants	16 Participants	18 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 4	40 Participants	18 Participants	6 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 5	4 Participants	16 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 6	5 Participants	11 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 7	4 Participants	12 Participants	1 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 8	4 Participants	3 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 9	1 Participants	7 Participants	1 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 10	0 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 11	0 Participants	3 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 12	2 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 13	1 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 3 16	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 3

minimum 0 to maximum 10, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=52 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 3	1 Participants	0 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 4	17 Participants	17 Participants	25 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 5	57 Participants	58 Participants	20 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 6	28 Participants	22 Participants	7 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 8	0 Participants	5 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 9	2 Participants	4 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 WHO scale 10	1 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Aspartate Aminotransferase (AST) at Day 3	48.67 Units/liter Standard Deviation 41.128	43.93 Units/liter Standard Deviation 36.497	48.53 Units/liter Standard Deviation 60.487

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Ferritin at Day 3	427.25 micrograms per liter Standard Deviation 194.8	1110 micrograms per liter Standard Deviation 6784.6	393.04 micrograms per liter Standard Deviation 170.2

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Lactate Dehydrogenase (LDH) at Day 3	404.45 international units per liter Standard Deviation 214.92	354.7 international units per liter Standard Deviation 204.2	351.27 international units per liter Standard Deviation 258.57

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
D-dimer at Day 3	0.23 μg/mL Standard Deviation 0.3321	0.29 μg/mL Standard Deviation 0.3845	0.244 μg/mL Standard Deviation 0.2211

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Alanine Aminotransferase (ALT) at Day 3	36.46 Units/liter Standard Deviation 32.585	36.16 Units/liter Standard Deviation 49.86	33.62 Units/liter Standard Deviation 34.535

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Albumin at Day 3	2.947 gm/dl Standard Deviation 0.4507	2.854 gm/dl Standard Deviation 0.504	3.157 gm/dl Standard Deviation 0.3858

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Bilirubin at Day 3	0.6457 milligram/deciliter Standard Deviation 0.654	0.7053 milligram/deciliter Standard Deviation 0.86	0.4793 milligram/deciliter Standard Deviation 0.255

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=82 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=52 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
C-reactive Protein (CRP) at Day 3	52.61 milligram/liter Standard Deviation 37.719	64.1 milligram/liter Standard Deviation 63.035	33.89 milligram/liter Standard Deviation 31.44

SECONDARY outcome

Timeframe: up to 60 days

duration of ICU stay

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Duration of Intensive Care Unit (ICU) Stay	7.6 days Standard Deviation 7.614	6.69 days Standard Deviation 6.23	1.45 days Standard Deviation 1.835

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
C-reactive Protein (CRP) at Day 7	47.43 milligram/liter Standard Deviation 52.631	65.73 milligram/liter Standard Deviation 90.34	14.06 milligram/liter Standard Deviation 14.548

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
C-reactive Protein (CRP) at Day 14	37.05 milligram/liter Standard Deviation 55.395	39.31 milligram/liter Standard Deviation 54.77	7.5 milligram/liter Standard Deviation 5.745

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
C-reactive Protein (CRP) at Day 28	39 milligram/liter Standard Deviation 38.419	96 milligram/liter Standard Deviation NA The number of participants is 1, so the Standard Deviation was not calculated	—

SECONDARY outcome

Timeframe: day 7

minimum 0 to maximum 24, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Sequential Organ Function Assessment (SOFA) Score on Day 7 0	1 Participants	1 Participants	5 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 1	4 Participants	4 Participants	18 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 2	10 Participants	10 Participants	12 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 3	13 Participants	13 Participants	3 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 4	28 Participants	7 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 5	7 Participants	7 Participants	1 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 6	6 Participants	5 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 11	3 Participants	3 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 12	0 Participants	3 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 13	1 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 14	1 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 15	1 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 16	0 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 7	2 Participants	6 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 8	1 Participants	4 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 9	2 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment (SOFA) Score on Day 7 10	4 Participants	2 Participants	0 Participants

SECONDARY outcome

Timeframe: day 14

minimum 0 to maximum 24, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=16 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Sequential Organ Function Assessment Score (SOFA) on Day 14 0	1 Participants	0 Participants	3 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 1	1 Participants	1 Participants	1 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 2	1 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 3	2 Participants	3 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 4	4 Participants	3 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 5	4 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 6	0 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 8	2 Participants	2 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 9	1 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 11	2 Participants	0 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 12	0 Participants	1 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 14	1 Participants	0 Participants	0 Participants
Sequential Organ Function Assessment Score (SOFA) on Day 14 16	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

minimum 0 to maximum 24, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Sequential Organ Function Assessment Score (SOFA) on Day 28 0	1 Participants	0 Participants	—
Sequential Organ Function Assessment Score (SOFA) on Day 28 3	1 Participants	0 Participants	—
Sequential Organ Function Assessment Score (SOFA) on Day 28 12	1 Participants	0 Participants	—
Sequential Organ Function Assessment Score (SOFA) on Day 28 13	1 Participants	0 Participants	—
Sequential Organ Function Assessment Score (SOFA) on Day 28 17	0 Participants	1 Participants	—

SECONDARY outcome

Timeframe: day 7

minimum 0 to maximum 10, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 4	20 Participants	21 Participants	28 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 9	7 Participants	4 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 10	0 Participants	6 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 5	28 Participants	22 Participants	11 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 6	26 Participants	16 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 8	3 Participants	5 Participants	0 Participants

SECONDARY outcome

Timeframe: day 14

minimum 0 to maximum 10, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=16 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14 4	2 Participants	7 Participants	4 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14 5	8 Participants	4 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14 6	3 Participants	1 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14 8	3 Participants	1 Participants	0 Participants
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14 9	3 Participants	3 Participants	0 Participants

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

minimum 0 to maximum 10, higher scores mean worse outcomes

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 28 5	2 Participants	0 Participants	—
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 28 9	2 Participants	0 Participants	—
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 28 10	0 Participants	1 Participants	—

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Aspartate Aminotransferase (AST) at Day 7	35.26 Units/liter Standard Deviation 20.089	41.35 Units/liter Standard Deviation 39.78	41.77 Units/liter Standard Deviation 32.465

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Aspartate Aminotransferase (AST) at Day 14	22.79 Units/liter Standard Deviation 13.319	30.19 Units/liter Standard Deviation 16.802	26.75 Units/liter Standard Deviation 18.118

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Aspartate Aminotransferase (AST) at Day 28	31 Units/liter Standard Deviation 11.605	27 Units/liter Standard Deviation NA The number of participants is 1, so the Standard Deviation was not calculated	—

SECONDARY outcome

Timeframe: day 7

Continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Alanine Aminotransferase (ALT) at Day 7	30.54 Units/liter Standard Deviation 23.062	33.90 Units/liter Standard Deviation 33.58	26 Units/liter Standard Deviation 18.604

SECONDARY outcome

Timeframe: day 14

Continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Alanine Aminotransferase (ALT) at Day 14	22.42 Units/liter Standard Deviation 15.788	35.38 Units/liter Standard Deviation 17.55	15.75 Units/liter Standard Deviation 4.856

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Alanine Aminotransferase (ALT) at Day 28	71.75 Units/liter Standard Deviation 57	39.5 Units/liter Standard Deviation NA The number of participants is 1, so the Standard Deviation was not calculated	—

SECONDARY outcome

Timeframe: day 7

Continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Bilirubin at Day 7	0.6575 milligram/deciliter Standard Deviation 0.699	0.8886 milligram/deciliter Standard Deviation 1.54	0.3717 milligram/deciliter Standard Deviation 0.221

SECONDARY outcome

Timeframe: day 14

Continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Bilirubin at Day 14	0.494 milligram/deciliter Standard Deviation 0.2229	0.6888 milligram/deciliter Standard Deviation 0.37	0.3625 milligram/deciliter Standard Deviation 0.11

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Bilirubin at Day 28	0.41 milligram/deciliter Standard Deviation 0.14376	1.67 milligram/deciliter Standard Deviation NA The number of participants is 1, so the Standard Deviation was not calculated	—

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Albumin at Day 7	2.77 gm/dl Standard Deviation 0.4837	2.644 gm/dl Standard Deviation 0.489	2.98 gm/dl Standard Deviation 0.4073

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Albumin at Day 14	2.82 gm/dl Standard Deviation 0.4184	2.813 gm/dl Standard Deviation 0.368	3.425 gm/dl Standard Deviation 0.2872

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Albumin at Day 28	2.575 gm/dl Standard Deviation 0.3304	2.7 gm/dl Standard Deviation NA The number of participants is 1, so the Standard Deviation was not calculated	—

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Platelets at Day 3	253.425 10^3 cells/uL Standard Deviation 105	226.35 10^3 cells/uL Standard Deviation 116.2	271.64 10^3 cells/uL Standard Deviation 97.62

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Platelets at Day 7	243.514 10^3 cells/uL Standard Deviation 116.2	212.76 10^3 cells/uL Standard Deviation 123.2	268.829 10^3 cells/uL Standard Deviation 93.9

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Platelets at Day 14	216.95 10^3 cells/uL Standard Deviation 126.3	215.63 10^3 cells/uL Standard Deviation 126.3	248 10^3 cells/uL Standard Deviation 136.48

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Platelets at Day 28	246.75 10^3 cells/uL Standard Deviation 113	15 10^3 cells/uL Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Serum Creatinine (S.Cr) at Day 3	0.9546 milligram/deciliter Standard Deviation 0.865	1.6568 milligram/deciliter Standard Deviation 1.776	1.0769 milligram/deciliter Standard Deviation 0.941

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Serum Creatinine (S.Cr) at Day 7	0.9952 milligram/deciliter Standard Deviation 0.987	1.6541 milligram/deciliter Standard Deviation 1.9	0.9674 milligram/deciliter Standard Deviation 0.752

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Serum Creatinine (S.Cr) at Day 14	0.6316 milligram/deciliter Standard Deviation 0.152	1.45 milligram/deciliter Standard Deviation 1.7753	0.775 milligram/deciliter Standard Deviation 0.221

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Serum Creatinine (S.Cr) at Day 28	0.525 milligram/deciliter Standard Deviation 0.1708	1.2 milligram/deciliter Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
D-dimer at Day 7	0.319 μg/mL Standard Deviation 0.5017	0.425 μg/mL Standard Deviation 0.5678	0.109 μg/mL Standard Deviation 0.1483

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
D-dimer at Day 14	0.41 μg/mL Standard Deviation 0.5999	0.313 μg/mL Standard Deviation 0.461	0.05 μg/mL Standard Deviation 0.1

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
D-dimer at Day 28	0.4 μg/mL Standard Deviation 0.8	0.4 μg/mL Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

SECONDARY outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Creatine Kinase (Ck) at Day 3	197.94 Units/liter Standard Deviation 342.1	181.45 Units/liter Standard Deviation 166	142.2 Units/liter Standard Deviation 135.12

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Creatine Kinase (Ck) at Day 7	211.9 Units/liter Standard Deviation 420.23	175.99 Units/liter Standard Deviation 155	126.743 Units/liter Standard Deviation 112

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Creatine Kinase (Ck) at Day 14	122.89 Units/liter Standard Deviation 93.259	142.75 Units/liter Standard Deviation 176	49.5 Units/liter Standard Deviation 30.116

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Creatine Kinase (Ck) at Day 28	119.22 Units/liter Standard Deviation 88.21	134.25 Units/liter Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Lactate Dehydrogenase (LDH) at Day 7	371.37 international units per liter Standard Deviation 196.2	349.68 international units per liter Standard Deviation 201	271.4 international units per liter Standard Deviation 165.99

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Lactate Dehydrogenase (LDH) at Day 14	360.89 international units per liter Standard Deviation 244.8	306.88 international units per liter Standard Deviation 266	379.75 international units per liter Standard Deviation 313.9

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Lactate Dehydrogenase (LDH) at Day 28	314.5 international units per liter Standard Deviation 108.99	270 international units per liter Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

SECONDARY outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Ferritin at Day 7	450.37 micrograms per liter Standard Deviation 247.6	1433 micrograms per liter Standard Deviation 8174	368.42 micrograms per liter Standard Deviation 167.8

SECONDARY outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Ferritin at Day 14	637.37 micrograms per liter Standard Deviation 436	519.88 micrograms per liter Standard Deviation 431	398.5 micrograms per liter Standard Deviation 131.43

SECONDARY outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Ferritin at Day 28	1355 micrograms per liter Standard Deviation 896.3	410 micrograms per liter Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

SECONDARY outcome

Timeframe: up to 60 days

Incidence of acute kidney injury (AKI)

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Incidence of Acute Kidney Injury (AKI) yes	4 Participants	7 Participants	1 Participants
Incidence of Acute Kidney Injury (AKI) no	102 Participants	99 Participants	52 Participants

SECONDARY outcome

Timeframe: up to 60 days

Incidence of acute liver damage (ALD)

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Incidence of Acute Liver Damage (ALD) yes	6 Participants	3 Participants	1 Participants
Incidence of Acute Liver Damage (ALD) no	100 Participants	103 Participants	52 Participants

SECONDARY outcome

Timeframe: up to 60 days

day of death

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Day of Death	12.57 day Standard Deviation 6.22	10.13 day Standard Deviation 6.530	0.19 day Standard Deviation 1.061

SECONDARY outcome

Timeframe: up to 60 days

mortality at discharge

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Mortality at Discharge dead	33 Participants	41 Participants	1 Participants
Mortality at Discharge alive	73 Participants	65 Participants	52 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: day 3

minimum 0 to maximum 15, higher scores mean better outcomes

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Glasgow Coma Score (GCS) at Day 3 3	3 Participants	6 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 4	1 Participants	0 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 6	1 Participants	0 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 7	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 8	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 9	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 10	2 Participants	10 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 12	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 3 13	0 Participants	3 Participants	1 Participants
Glasgow Coma Score (GCS) at Day 3 14	5 Participants	6 Participants	1 Participants
Glasgow Coma Score (GCS) at Day 3 15	94 Participants	77 Participants	51 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: day 3

continuous level

Outcome measures

Measure	Remdesivir n=106 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=106 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=53 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3	154.14 Ratio Standard Deviation 138.9	166.96 Ratio Standard Deviation 130	298.57 Ratio Standard Deviation 211.3

OTHER_PRE_SPECIFIED outcome

Timeframe: day 7

continuous level

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7	163.55 Ratio Standard Deviation 172.6	178.59 Ratio Standard Deviation 138	320.62 Ratio Standard Deviation 93.64

OTHER_PRE_SPECIFIED outcome

Timeframe: day 14

continuous level

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14	154.67 Ratio Standard Deviation 174	165.2 Ratio Standard Deviation 98.87	389.75 Ratio Standard Deviation 51.93

OTHER_PRE_SPECIFIED outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

continuous level

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 28	172.75 Ratio Standard Deviation 181	53 Ratio Standard Deviation NA Standard Deviation not calculable as only 1 participant was analyzed	—

OTHER_PRE_SPECIFIED outcome

Timeframe: day 7

minimum 0 to maximum 15, higher scores mean better outcomes

Outcome measures

Measure	Remdesivir n=84 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=74 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=39 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Glasgow Coma Score (GCS) at Day 7 3	10 Participants	13 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 6	1 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 7	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 9	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 10	3 Participants	11 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 12	0 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 13	1 Participants	1 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 14	3 Participants	3 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 7 15	66 Participants	42 Participants	39 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: day 14

minimum 0 to maximum 15, higher scores mean better outcomes

Outcome measures

Measure	Remdesivir n=19 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=13 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab n=4 Participants casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Glasgow Coma Score (GCS) at Day 14 3	6 Participants	4 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 14 10	0 Participants	0 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 14 13	1 Participants	0 Participants	0 Participants
Glasgow Coma Score (GCS) at Day 14 15	11 Participants	7 Participants	4 Participants
Glasgow Coma Score (GCS) at Day 14 14	1 Participants	2 Participants	0 Participants

OTHER_PRE_SPECIFIED outcome

Timeframe: day 28

Population: patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

minimum 0 to maximum 15, higher scores mean better outcomes

Outcome measures

Measure	Remdesivir n=4 Participants Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug	Favipravir n=1 Participants Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug	Casirivimab and Imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Glasgow Coma Score (GCS) at Day 28 3	2 Participants	1 Participants	—
Glasgow Coma Score (GCS) at Day 28 15	2 Participants	NA Participants Standard Deviation not calculable as only 1 participant was analyzed	—

Adverse Events

Casirivimab and Imdevimab

Serious events: 0 serious events

Other events: 0 other events

Deaths: 1 deaths

Remdesivir

Serious events: 0 serious events

Other events: 0 other events

Deaths: 34 deaths

Favipravir

Serious events: 0 serious events

Other events: 0 other events

Deaths: 43 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Ahmed Hosny

Mansoura University Hospital

Phone: +2001554658010

Email: ahmedony26@gmail.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place